Form 4: C4 Therapeutics Executive Kelly Schick Reports Stock Transactions
SEC Form 4 Filing
Kelly Schick, Chief People Officer at C4 Therapeutics, reports the vesting of performance restricted stock units and shares withheld for tax obligations.
Summary
- On September 16, 2024, Kelly Schick, Chief People Officer of C4 Therapeutics, reported transactions involving the company's common stock.
- Schick acquired 2,250 shares of common stock through the vesting of performance restricted stock units (PRSUs).
- 661 shares were withheld by C4 Therapeutics to satisfy tax withholding obligations related to the vesting of the PRSUs at a price of $6.36.
- Following these transactions, Schick directly owns 53,840 shares of C4 Therapeutics common stock and 14,250 performance restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing reflecting standard executive compensation practices, with no inherent positive or negative implications for the company's overall outlook.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their stock transactions. It is standard practice for executives to receive and vest stock options or restricted stock units as part of their compensation packages.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect standard executive compensation and do not indicate a change in the company's fundamentals.
Key Dates
| Date | Description |
|---|---|
| 09/16/2024 | Date of stock transactions (vesting of PRSUs and tax withholding). |
| 09/17/2024 | Date of signature for the Form 4 filing. |
| 02/28/2025 | Expiration date of the Performance Restricted Stock Units |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.